PTIX — Protagenic Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing
Brief: Protagenic Therapeutics Granted Japanese Patent JP 7714571B
Brief: Protagenic Therapeutics Enters Share Exchange Agreement With Alterola And EMC2 - SEC Filing
Brief: Protagenic Therapeutics - May Offer And Sell, From Time To Time, Shares Of Common Stock Of Up To $1.2 Mln
Brief: Protagenic Therapeutics Inc - On Nov 19, Co Receives Nasdaq Delist Determination Letter
Brief: Protagenic Therapeutics Inc Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing
Brief: Protagenic Therapeutics Stress-Regulating Peptide Demonstrates Exceptional Safety In Single Dose Portion Of Phase I Trial
Brief: Protagenic Therapeutics Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Protagenic Therapeutics To Effect 1-For-4 Reverse Stock Split
Brief: Protagenic Therapeutics Inc - Expects To Commence Clinical Trials In Q4 Of 2022
Brief: Protagenic Says Submitting Appropriate Filing In Europe To Commence Phase I/Iia Trial At Major Cro Site In Germany
Brief: Protagenic Therapeutics Inc - Now In Compliance With Nasdaq Requirement.
Brief: Protagenic Says Entered Into At Market Issuance Sales Agreement With B. Riley Securities, EF Hutton
Brief: Protagenic Files For Mixed Shelf Of Up To $100 Million
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:44 AM
Brief: Protagenic Therapeutics Announces Nasdaq Uplisting And Pricing Of $13.2 Mln Public Offering
Brief: Protagenic Therapeutics Inc Applied To List Common Stock And Warrants On Nasdaq